Summary
Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmann DL, Bisel HF, Hahn RG (1974) Phase II clinical trial of isophosphamide in patients with advanced breast cancer. Cancer Chemother Rep 58:861–865
Ahmann DL, Hahn RG, Bisel HF (1982) A phase II evaluation of ifosfamide (NSC 109724) treatment of disseminated breast cancer. (Abstract) Proc Am Assoc Cancer Res 15:794
Brade WP, Herdrick K, Varini M (1985) Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1–47
Brade WP, Herdrich K, Klein HO (1987) Ifosfamide-dosing and scheduling. In: Ifosfamide in tumor therapy. Brade WP, Nagel GA, Seeber S (eds) Karger, Basel, pp 22–52 (Contributions to oncology, vol 26)
Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet II:657–659
Cantwell BMJ, Harris AL (1985) Ifosfamide/mesna and encephalopathy. Lancet I:752
Creaven PJ, Allen LM, Cohen MH, Nelson RL (1976) Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rev 60:445–449
Falkson G, Falkson HC (1976) Further experiences with iphosphamide. Cancer Treat Rep 60:955–957
Heim ME (1981) Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 100:113–116
Klein HO, Wickramanayake PD, Coerper CL (1983) High-dose ifosfamide and mesna as continuous infusion over five days—a phase I/II trial. Cancer Treat Rev 10:167–173
Miller AB, Hoogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47:207–214
Pratt CB, Goren MB (1987) Ifosfamide/mesna and hematuria. Cancer Treat Rep 71:1124–1125
Schnitker J (1976) Evaluation of the cytostatic agent ifosfamide. Arzneimittelforschung 26:1783–1793
Van Dyck JJ, Falkson HC, Van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32:921–924
Varini M (1987) Ifosfamide in tumor therapy—an overview. In: Ifosfamide in tumor therapy. Brade WP, Nagel GA, Seeber S (eds) Karger, Basel, pp 12–21 (Contributions to oncology, vol 26)
World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva (WHO offset publication no 48)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steger, G.G., Dittrich, C., Schlappack, O. et al. Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer. J Cancer Res Clin Oncol 114, 602–604 (1988). https://doi.org/10.1007/BF00398184
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00398184